Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
49
datasets available to search
ShareScore release 0.9.0
Dataset results
49 results for “BCMA CAR-T Therapy”
Reconstitution of the multiple myeloma microenvironment following lymphodepletion with BCMA CAR-T therapy
<p>BCMA-targeted CAR-T therapy has shown potent treatment outcomes in treating multiple myeloma (MM), a disease characterized by malignant bone marrow (BM) plasma cells. However, the remodeling of MM microenvironment after CAR-T therapy remains poorly understood. Here, we report the reconstitution of MM microenvironment by obtaining single-cell transcriptomes for paired BM specimens (n = 14) from 7 MM patients before (<em>i.e.</em>, baseline, ''day −4'') and after (<em>i.e.</em>, ''day 28'') post-lymphodepleted BCMA CAR-T therapy. Our analysis revealed heterogeneity in driver gene expression among MM cells, even those harboring the same cytogenetic abnormalities. The best overall responses of patients over the 15-month follow-up are positively correlated with the abundance and targeted cytotoxic activity of CD8<sup>+</sup> effector CAR-T cells on day 28 after CAR-T cell infusion. Additionally, favorable responses are associated with attenuated immunosuppression mediated by regulatory T cells (Tregs), enhanced CD8<sup>+</sup> effector T cell cytotoxic activity, and elevated type 1 conventional dendritic cell (cDC1) antigen presentation ability. DC re-clustering inferred intramedullary-originated cDC3s with extramedullary migration. Cell-cell communication network analysis indicated BCMA CAR-T therapy mitigates BAFF/GALECTIN/MK pathway-mediated immunosuppression and activates MIF pathway-mediated anti-MM immunity. Our study sheds light on MM microenvironment dynamics after BCMA CAR-T therapy, offering clues for predicting treatment responsivity.</p>
Safety and Efficacy of CD19-BCMA Targeted CAR-T Therapy for Refractory Generalized Myasthenia Gravis
ClinicalTrials.gov study NCT06371040. IPD Sharing: YES. Countries: 1. Publications: 0.
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma
ClinicalTrials.gov study NCT03548207. IPD Sharing: Not stated. Countries: 2. Publications: 11.
A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethason
ClinicalTrials.gov study NCT04181827. IPD Sharing: YES. Countries: 16. Publications: 8.
Reconstitution of the multiple myeloma microenvironment following lymphodepletion with BCMA CAR-T therapy
Open the record for dataset details and reuse information.
Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma
ClinicalTrials.gov study NCT04706936. IPD Sharing: NO. Countries: 1. Publications: 1.
A Study of VRd-based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With New-diagnosed Multiple Myeloma
ClinicalTrials.gov study NCT05860036. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myel
ClinicalTrials.gov study NCT03758417. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study of BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma
ClinicalTrials.gov study NCT05430945. IPD Sharing: NO. Countries: 1. Publications: 2.
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma
ClinicalTrials.gov study NCT04133636. IPD Sharing: YES. Countries: 8. Publications: 1.
Safety and Efficacy of Anti-BCMA/GPRC5D CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma(rr/MM)
ClinicalTrials.gov study NCT05509530. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Clinical Study to Evaluate the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Received Three or More Lines of Therapy
ClinicalTrials.gov study NCT05998928. IPD Sharing: NO. Countries: 1. Publications: 2.
Exploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related Disease
ClinicalTrials.gov study NCT07148791. IPD Sharing: NO. Countries: 1. Publications: 4.
A Study of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma
ClinicalTrials.gov study NCT04670055. IPD Sharing: NO. Countries: 1. Publications: 1.
Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies
ClinicalTrials.gov study NCT05191472. IPD Sharing: NO. Countries: 1. Publications: 0.
Single-cell transcriptomic sequencing of BCMA CAR-T cells during CAR-T therapy in refractory primary plasma cell leukemia
GEO Series GSE151310. Homo sapiens. 20 samples. Type: Expression profiling by high throughput sequencing.
CD4+ CAR-T cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR-T cell therapy
GEO Series GSE274187. Homo sapiens. 23 samples. Type: Expression profiling by high throughput sequencing; Other.
CD4+ CAR-T cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR-T cell therapy I
GEO Series GSE246342. Homo sapiens. 18 samples. Type: Expression profiling by high throughput sequencing; Other.
CD4+ CAR-T cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR-T cell therapy II
GEO Series GSE274185. Homo sapiens. 5 samples. Type: Expression profiling by high throughput sequencing.
Identification of molecular mechanisms promoting long-term cytopenia after BCMA CAR-T therapy in Multiple Myeloma
GEO Series GSE250444. Homo sapiens. 2 samples. Type: Expression profiling by high throughput sequencing.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.